Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

This publication has 20 references indexed in Scilit:

• Biochemical and Immunological Characterization of Bacterially Expressed and RefoldedPlasmodium falciparum42-Kilodalton C-Terminal Merozoite Surface Protein 1
  Infection and Immunity, 2003
• Rate of Degradation of α-Tocopherol, Squalene, Phenolics, and Polyunsaturated Fatty Acids in Olive Oil during Different Storage Conditions
  Journal of Agricultural and Food Chemistry, 2002
• A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New Guinea
  The Journal of Infectious Diseases, 2002
• A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers
  Vaccine, 2001
• Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect Mosquitoes
  Infection and Immunity, 2000
• Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
  Vaccine, 2000
• Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoid
  Vaccine, 1999
• Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
  Vaccine, 1997
• The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity
  Vaccine, 1992
• SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE
  The Lancet, 1987